메뉴 건너뛰기




Volumn 24, Issue SUPPL. 9, 1996, Pages 7-27

Cerivastatin, a new inhibitor of HMG-CoA reductase - Pharmacokinetics in rats and dogs

Author keywords

Absorption; BAY w 6228; CAS 143201 11 0; Cerivastatin; Distribution; Excretion; HMG CoA reductase inhibitor; Interaction; Mammary excretion; Organ distribution; Pharmacokinetics; Placental transfer; Preclinical; Protein binding; Whole body autoradiography

Indexed keywords

CAS 143201; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; PLASMA PROTEIN; SERUM ALBUMIN; UNCLASSIFIED DRUG;

EID: 0029853471     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (20)

References (13)
  • 2
    • 33745501400 scopus 로고    scopus 로고
    • Pharmacology of the new highly potent HMG-CoA reductase inhibitor cerivastatin (BAY w 6228)
    • in preparation
    • Bischoff H et al : Pharmacology of the new highly potent HMG-CoA reductase inhibitor cerivastatin (BAY w 6228). Atherosclerosis (in preparation)
    • Atherosclerosis
    • Bischoff, H.1
  • 4
    • 33745445262 scopus 로고    scopus 로고
    • Metabolism of cerivastatin by human liver microsomes in vitro : Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved
    • in preparation
    • Boberg M et al : Metabolism of cerivastatin by human liver microsomes in vitro : Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos (in preparation)
    • Drug Metab Dispos
    • Boberg, M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.